444 related articles for article (PubMed ID: 11312654)
1. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites.
Kitchin KT
Toxicol Appl Pharmacol; 2001 May; 172(3):249-61. PubMed ID: 11312654
[TBL] [Abstract][Full Text] [Related]
2. [Current progress in animal models of arsenic carcinogenesis].
An Y
Wei Sheng Yan Jiu; 2006 Nov; 35(6):814-8. PubMed ID: 17290776
[TBL] [Abstract][Full Text] [Related]
3. Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment.
Kitchin KT; Conolly R
Chem Res Toxicol; 2010 Feb; 23(2):327-35. PubMed ID: 20035570
[TBL] [Abstract][Full Text] [Related]
4. Understanding arsenic carcinogenicity by the use of animal models.
Wanibuchi H; Salim EI; Kinoshita A; Shen J; Wei M; Morimura K; Yoshida K; Kuroda K; Endo G; Fukushima S
Toxicol Appl Pharmacol; 2004 Aug; 198(3):366-76. PubMed ID: 15276416
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress as a possible mode of action for arsenic carcinogenesis.
Kitchin KT; Ahmad S
Toxicol Lett; 2003 Jan; 137(1-2):3-13. PubMed ID: 12505428
[TBL] [Abstract][Full Text] [Related]
6. Arsenic carcinogenesis in the skin.
Yu HS; Liao WT; Chai CY
J Biomed Sci; 2006 Sep; 13(5):657-66. PubMed ID: 16807664
[TBL] [Abstract][Full Text] [Related]
7. Role of the alkali labile sites, reactive oxygen species and antioxidants in DNA damage induced by methylated trivalent metabolites of inorganic arsenic.
Soto-Reyes E; Del Razo LM; Valverde M; Rojas E
Biometals; 2005 Oct; 18(5):493-506. PubMed ID: 16333750
[TBL] [Abstract][Full Text] [Related]
8. Arsenic-induced bladder cancer in an animal model.
Cohen SM; Ohnishi T; Arnold LL; Le XC
Toxicol Appl Pharmacol; 2007 Aug; 222(3):258-63. PubMed ID: 17109909
[TBL] [Abstract][Full Text] [Related]
9. Effects of inorganic arsenic on the rat and mouse urinary bladder.
Suzuki S; Arnold LL; Ohnishi T; Cohen SM
Toxicol Sci; 2008 Dec; 106(2):350-63. PubMed ID: 18728046
[TBL] [Abstract][Full Text] [Related]
10. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?
Snow ET; Sykora P; Durham TR; Klein CB
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):557-64. PubMed ID: 15996700
[TBL] [Abstract][Full Text] [Related]
11. Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis.
Rossman TG; Uddin AN; Burns FJ; Bosland MC
Toxicol Appl Pharmacol; 2001 Oct; 176(1):64-71. PubMed ID: 11578149
[TBL] [Abstract][Full Text] [Related]
12. Animal models for arsenic carcinogenesis: inorganic arsenic is a transplacental carcinogen in mice.
Waalkes MP; Liu J; Ward JM; Diwan BA
Toxicol Appl Pharmacol; 2004 Aug; 198(3):377-84. PubMed ID: 15276417
[TBL] [Abstract][Full Text] [Related]
13. Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective.
Tseng CH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2007; 25(1):1-22. PubMed ID: 17365340
[TBL] [Abstract][Full Text] [Related]
14. Dose response evaluation of gene expression profiles in the skin of K6/ODC mice exposed to sodium arsenite.
Ahlborn GJ; Nelson GM; Ward WO; Knapp G; Allen JW; Ouyang M; Roop BC; Chen Y; O'Brien T; Kitchin KT; Delker DA
Toxicol Appl Pharmacol; 2008 Mar; 227(3):400-16. PubMed ID: 18191166
[TBL] [Abstract][Full Text] [Related]
15. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
[TBL] [Abstract][Full Text] [Related]
16. The cellular metabolism and systemic toxicity of arsenic.
Thomas DJ; Styblo M; Lin S
Toxicol Appl Pharmacol; 2001 Oct; 176(2):127-44. PubMed ID: 11601889
[TBL] [Abstract][Full Text] [Related]
17. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water.
Kenyon EM; Hughes MF; Adair BM; Highfill JH; Crecelius EA; Clewell HJ; Yager JW
Toxicol Appl Pharmacol; 2008 Nov; 232(3):448-55. PubMed ID: 18706920
[TBL] [Abstract][Full Text] [Related]
18. Folate deficiency enhances arsenic effects on expression of genes involved in epidermal differentiation in transgenic K6/ODC mouse skin.
Nelson GM; Ahlborn GJ; Delker DA; Kitchin KT; O'Brien TG; Chen Y; Kohan MJ; Roop BC; Ward WO; Allen JW
Toxicology; 2007 Nov; 241(3):134-45. PubMed ID: 17928125
[TBL] [Abstract][Full Text] [Related]
19. Arsenic toxicity at low doses: epidemiological and mode of action considerations.
Schoen A; Beck B; Sharma R; Dubé E
Toxicol Appl Pharmacol; 2004 Aug; 198(3):253-67. PubMed ID: 15276404
[TBL] [Abstract][Full Text] [Related]
20. Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells.
Dopp E; Hartmann LM; Florea AM; von Recklinghausen U; Pieper R; Shokouhi B; Rettenmeier AW; Hirner AV; Obe G
Toxicol Appl Pharmacol; 2004 Dec; 201(2):156-65. PubMed ID: 15541755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
